Chimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Josh Allen - Chief Technology Officer of Imipridones Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Joseph Thome - TD Cowen Naureen Quibria - Capital One Securities Soumit Roy ...

公司未来发展前景 - 公司预计在可预见的未来将继续承担重大损失，可能永远无法实现或维持盈利[8] - 公司所有产品候选者仍处于临床开发阶段，可能无法获得监管批准或成功商业化[9] - 公司可能无法获得或延迟获得对临床候选者的监管批准，包括我们最先进的临床候选者ONC201[10] - 公司未来收入的生成能力存在不确定性，取决于我们成功开发、获得对产品候选者的监管批准并商业化的能力，即使我们产生未来收入，也可能不足以实现盈利[11] - 如果我们获得对任何产品候选者的监管批准，包括ONC201，我们仍将面临广泛的监管要求，我们的产品可能面临未来的开发和监管困难[12]

Chimerix, Inc. (NASDAQ:CMRX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning & Investor Relations Mike Sherman - Chief Executive Officer Mike Andriole - Chief Business Officer & Chief Financial Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Ed White - H.C. Wainwright Joseph Thome - Cowen Operator Good morning, ladies and gentlemen, and we ...

Chimerix, Inc. (NASDAQ:CMRX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Michelle LaSpaluto – Vice President-Strategic Planning and Investor Relations Mike Sherman – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Mike Andriole – Chief Financial and Business Officer Randall Lanier – Chief Science Officer Josh Allen – Chief Technology Officer-Imipridones Conference Call Participants Maury Raycroft – Jefferies Joseph Thome – Cowen Ed White – H.C. ...

Chimerix, Inc. (NASDAQ:CMRX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Mike Sherman – President & Chief Executive Officer Michael Andriole – Chief Financial & Business Officer Allen Melemed – Chief Medical Officer Joshua Allen – Chief Technology Officer, Imipridones Michelle Laspaluto – Vice President, Strategic Planning & Investor Relations Conference Call Participants Maury Raycroft – Jefferies Edward White – H.C. Wainwright & Co. Naureen Quibria – Maxim Group Soumit Ro ...

Chimerix 1Q2022 Corporate Presentation Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, results from the BICR of the 50- patient cohort of ONC201 for the treatment of recurrent H3 K27M-mutant glioma, the status of Ch ...

Chimerix, Inc. (NASDAQ:CMRX) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President, Strategic Planning & Investor Relations Mike Sherman - President & Chief Executive Officer Randall Lanier - Chief Science Officer Mike Andriole - Chief Financial & Business Officer Allen Melemed - Chief Medical Officer Josh Allen - Chief Technology Officer, Imipridones Conference Call Participants Maury Raycroft - Jefferies Naureen Quibria - Maxim Group Ed White - ...

Chimerix January 2022 Corporate Presentation Forward-Looking Statements 2 These slides contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the status of Chimerix's oncology programs, and the results of the 50-patient efficacy analysis of ONC201, including thos ...

Chimerix, Inc. (NASDAQ:CMRX) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Josh Allen - Chief Technology Officer of Imipridones Conference Call Participants Maury Raycroft - Jefferies Joseph Thome - Cowen and Company Naureen Quibria - Maxim Group Soum ...

Chimerix 2Q21 Corporate Presentation Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop and commercialize its drug candidates including ONC201, DSTAT and TEMBXA®; the sufficiency of the da ...